According to the contract research organization (CRO), BLS, also a CRO, has been building a bioanalytical research center specializing in complex method development, method validation, and biological sample analysis for pre-clinical and clinical drug trials (BA/BE studies), over the past three years.
The center was led by Lab Director, Nicola Hughes, Ph.D, who will now serve on BioPharma’s Executive Team as the Vice-President of Lab Operations.
Through the acquisition, BLS assets will be combined with BioPharma’s existing Bioanalytical Lab – further expanding the company’s analytical services.
Renzo DiCarlo, BioPharma Services CEO commented that under Hughes’ leadership, the expanded lab will “immediately offer challenging and complex new assays,” which he said is just one of many benefits associated with the labs merging assets.
Any current BLS client projects will be completed as planned at the existing BLS facility.